A Rs 31,500 Crore Issue Needs a Bigger Tower: Building POSI Capacity for India's Largest IPOs

The NSE initial public offering is expected in the second half of September 2026 and could raise around Rs 31,500 crore at a valuation of Rs 5.2 to 5.3 lakh crore, at an expected price of Rs 2,100 to 2,300 per share (India Infoline, 2026; Business Today, 31 July 2026). At that size it would pass Hyundai Motor India's Rs 27,870 crore issue and stand as the largest IPO in Indian history. NSE chief executive Ashishkumar Chauhan has confirmed that the exchange has received a no-objection certificate from SEBI.

It is not arriving alone. Close to Rs 45,000 crore is expected to be mobilised in September 2026 across the NSE issue, Zepto and six mainboard IPOs (IPO Central, 2026). Zepto filed its updated draft red herring prospectus in June 2026, comprising a fresh issue of Rs 8,010 crore and an offer for sale of up to 11.35 crore shares by early investors, with listing expected in the July to September 2026 window.

For an insurance buyer the headline capital figure is the least interesting number in that paragraph. What matters is that seven or eight separate offer documents, each carrying its own statutory prospectus liability, will be seeking cover from the same finite pool of Indian financial-lines capacity inside a few weeks of each other. Indian POSI towers have historically been assembled for issues an order of magnitude smaller. The product works at this scale. The placement mechanics do not scale by themselves.

There is no published Indian benchmark that converts issue size into a POSI limit, and any broker who quotes one as though it were settled market practice is describing a habit rather than a method. The limit has to be argued from the exposure.

The exposure base is not market capitalisation. It is the value of securities placed with subscribers who could plausibly allege that they relied on the offer document, plus the cost of defending them. Those two components behave differently. Defence cost is the near-certain spend, incurred from the first regulatory query onward whether or not any claim succeeds. Indemnity is the tail.

The factors that move the limit in an Indian placement are reasonably consistent:

1. The size of the raise, and within it the split between the fresh issue and the offer for sale, because an offer for sale broadens the set of parties who may need to be insured.
2. The retail and HNI allocation, since a wide retail book raises the probability of an investor grievance route being used and of SEBI taking an interest.
3. Disclosure complexity, which is where loss-making issuers, novel unit economics, related-party structures and regulated-entity issuers all sit.
4. Forum exposure, meaning whether the offering was marketed to investors who could sue outside India.
5. The company's existing directors and officers programme, because a POSI limit only earns its place if it keeps the offering exposure out of that tower.

Run the arithmetic before the market survey rather than after it. A limit chosen after seeing what capacity happens to be available is a limit chosen by the market's appetite, not by the board's exposure, and it becomes very difficult to defend to a shareholder plaintiff's counsel three years later.

No Indian general insurer writes a mega POSI limit on its own account. Two constraints bind. The first is the insurer's net retention for financial lines, which is a small fraction of what it retains on property. The second is the capacity available under its proportional treaty for the financial-lines class, which is set once a year and is not sized for a single issue of this magnitude.

What a carrier can offer on an individual submission is therefore its treaty-supported line, and above that only whatever facultative support it can raise for that specific risk. The practical consequence is that a large POSI programme is a syndicated tower, not a policy:

• A primary layer, written by a lead carrier that negotiates the wording, sets the terms and takes claims control.
• Several excess layers, each with its own participants, each following the primary form subject to its own layer wording.
• A reinsurance panel sitting behind every one of those participants, comprising the obligatory cession to GIC Re, proportional treaty support, and then facultative reinsurance for the balance.

The last item is the binding constraint in a crowded month. Facultative capacity for Indian prospectus liability is concentrated in a small group of reinsurance underwriters in London, Singapore and Dubai. When several Indian mega-issues submit inside the same fortnight, those underwriters see all of them, and their aggregate appetite for Indian securities-claim exposure is set at a portfolio level. Whoever submits first, with a complete due-diligence file, gets quoted first.

Once the domestic tower is exhausted, there are two routes to more capacity, and they are not interchangeable.

The GIFT City route

IFSC insurance offices and IFSC insurance intermediary offices at GIFT City write business under the IFSCA framework rather than under a domestic licence. For a mega issue this matters in a specific way: an IIO can commit balance-sheet capacity that is offshore in accounting terms while sitting inside the Indian regulatory perimeter for placement purposes. Cessions to IFSC insurance offices are recognised within the order of preference that IRDAI's reinsurance regulations impose on Indian cedants, which is the difference between a compliant top-up layer and a placement that has to be justified after the fact.

The cross-border route

Beyond that sit cross-border reinsurers, which come last in the cession order of preference and carry rating and filing requirements. They also come with practical friction on a securities claim: currency of settlement, the time it takes to move a claim payment into India, and whether the reinsurer will fund defence costs as they are incurred or only on indemnification.

There is a separate reason a placement goes offshore that has nothing to do with capacity. An issuer with a material overseas investor base, an offering marketed under Rule 144A or Regulation S, or a group with a listed foreign parent may need a master policy written outside India with an Indian local policy underneath. That is a structuring decision driven by where a claim can be brought, and it should be taken at the same time as the limit decision rather than bolted on at the end of the placement.

POSI is written for a fixed multi-year term with no renewal and no annual re-underwriting. Once the term is bound and the premium paid, the decision is closed. That makes term length the single most consequential structural choice in the placement after the limit.

The liability the term has to outlast is statutory. Sections 34, 35 and 36 of the Companies Act, 2013 create criminal liability for misstatements in a prospectus, civil liability to investors who subscribed on the faith of it, and liability for fraudulently inducing investment, and SEBI's disclosure regime layers regulatory exposure on top of that.

Securities claims do not surface on the listing date. They surface when something contradicts the offer document, and the recognisable trigger points fall in a predictable sequence:

1. The first two or three sets of annual results measured against the projections and risk factors in the prospectus.
2. Lock-in expiry and the first large sell-down by pre-IPO holders.
3. A restatement, an auditor qualification, or a change of auditor.
4. A SEBI order, a search, or an adjudication proceeding touching the disclosures.

Market terms of three, five, six and seven years are all available. The premium for the additional years is paid once, at inception, and it is materially cheaper than the alternative, because there is no market for extending a POSI term retroactively once a claim is visible on the horizon. For an issue at the NSE's expected scale, buying the short term to save premium is a false economy that the board will be asked about if a claim lands in year four.

Zepto's updated DRHP pairs a Rs 8,010 crore fresh issue with an offer for sale of up to 11.35 crore shares by early investors. That structure, common across the September book, changes who needs to be on the policy.

A fresh issue puts the company and its board in the frame. An offer for sale adds selling shareholders who take money out of the offering and who make their own statements in the offer document, typically confirming their title to the shares and accepting responsibility for the statements about themselves. Where those shareholders are institutional funds, their nominee directors, their fund entities and their general partners can all be drawn into a claim.

The insured schedule therefore has to be negotiated, not inherited from a template:

• The issuer company, its directors, officers and employees who signed or contributed to the prospectus.
• Selling shareholders, in respect of the statements for which they have taken responsibility.
• Nominee directors appointed by selling shareholders, whose exposure runs both to the fund and to the issuer.
• Persons named as experts in the offer document, where they are within the intended cover.
• The book running lead managers, where the underwriting agreement requires the issuer to indemnify them and the POSI is intended to stand behind that contractual indemnity.

Three wording points decide whether that schedule works. Severability and non-imputation must be drafted so that fraud or a deliberate misstatement by one selling shareholder does not void cover for independent directors who knew nothing about it. The insured versus insured exclusion must be cut back so that a claim brought by a selling shareholder against the issuer, or the reverse, is not automatically excluded. And allocation must be agreed in advance for the case where the issuer and a selling shareholder are co-defendants with different degrees of culpability, since an unallocated defence spend on a multi-defendant securities claim erodes a shared limit quickly. Get these into the policy wording at quotation stage; they are close to unnegotiable once the slip is signed.

A mega POSI placement is a project with a fixed end date, and the end date is the prospectus date. Working backwards from it:

1. Ten to twelve weeks out. Limit sizing memo agreed with the board and the audit committee, structure decided (single tower, or a domestic tower with a GIFT City or offshore top-up), and the insured schedule drafted against the actual offer structure.
2. Eight to ten weeks out. Submission to the lead market, built around the DRHP or UDRHP, the due-diligence file, the legal opinions and the comfort letters. A complete file gets quoted; an incomplete one goes to the back of an underwriter's queue in a month like this one.
3. Six to eight weeks out. Lead terms and wording negotiation, including severability, insured versus insured, allocation and the run-off term. Management meeting with the lead underwriter and, for a large tower, with the principal reinsurers.
4. Four to six weeks out. Excess layers built, with follow-form language checked layer by layer rather than assumed.
5. Before the RHP is filed. Slip signed, premium settled, cover incepting on the prospectus date.

Sarvada runs this as a broking mandate: exposure-based limit sizing, a market survey that covers domestic carriers, GIFT City IIOs and the offshore reinsurance panel together rather than in sequence, wording negotiation on the points above, and a placement calendar that accounts for the other issues competing for the same capacity. For issuers who also need to reset the ongoing management-liability programme for life as a listed company, the post-IPO D&O step-change is a separate exercise that should run in parallel, not after listing.